For the past decade, we have accumulated expertise covering the entire product development process, ranging from basic research, T cell engineering and development, and preclinical/clinical trial and assessment.
Led by industry and academic experts from our base in Singapore, we are dedicated to the commercialization and continued development of our immunotherapy products in the world.
Scientific Founder & Chairman
Prof Antonio Bertoletti is named top 0.1% Hepatitis B Expert in the World over the past 10 years (Expertscape in 2019). He was the Director of Infection and Immunity Program at the Singapore Institute for Clinical Sciences (SICS) under A*STAR until 2013. Currently, he is a professor in the Division Emerging Infectious Diseases at Duke-NUS Graduate Medical School. Prof Antonio was trained as a specialist in Infectious Diseases and has always been interested in immunological control of persistent viral infections, particularly Hepatitis B (HBV). His current research focuses on the development of new immunological based therapies (TCR-redirected T cells, HLA-peptide specific antibodies) for the treatment of HBV and Hepatocellular carcinoma (HCC), and the characterization of human intra-sinusoidal hepatic immune system. Prof Antonio and his team have received the 1st Prize Award based on the first in the world using HBV-specific TCR-T for liver cancer. He has been holding scientific advisor role for Gilead, MedImmune, Vir Biotechnology and Janssen. To learn more about his lab: http://www.bertolettilab.com
Chief Executive Officer
Dr Peng obtained his PhD degree from National University of Singapore (NUS) and holds Adjunct Associate Professor at NUS, he has over 18 years working experience at A*STAR holding senior positions including Head of Division & Senior Scientist, Deputy Director of the Strategic Planning for China. With over two decades of experience in R&D and team management, he has accumulated tens of millions research grants and funding from industry partners.
Chief Operating Officer
Dr Wang is a medical doctor. She obtained her PhD degree from National University of Singapore (NUS), and has over 20 years experience in the field of oncology in biopharmaceutical industry, clinical practice and translational medical research. She led the Asia Pacific medical team for the successful pre-launch and launch of VENTANA PD-L1 assays (SP142 and SP263) at Roche Diagnostics APAC. She has driven the advanced CD30 CAR-T cell therapy into clinical trials and led the FDA IND clearance to treat lymphoma patients at Tessa Therapeutics.
Dr Anthony obtained his Ph.D. from National University of Singapore in 2012 and is currently a Senior post-doctoral research fellow in the Lab of Prof Antonio at Duke-NUS Medical School. He has over 9 years of extensive experience in immunology and virology at Dr. Antonio Bertoletti’s laboratory and is experienced in the selection of antigen targets in viral infection-related cancer, the construction of T cell receptors, and in conducting preclinical research in animal models. He is responsible for the identification of tumor antigens, new diagnostic methods and the new method of developing T cell receptors at Lion TCR.
Director of Technology and Manufacturing Department
Dr Koh was an A*STAR scholar and obtained her PhD in Medical Science from Karolinska Institute, Sweden in 2013. She was a post-doctoral fellow in the laboratory of Professor Antonio Bertoletti at Singapore Institute for Clinical Sciences (SICS) of A*STAR. Her current R&D and product development interests are focused on T-cell immunotherapy and the immuno-pathogenesis of hepatitis B virus infection. Since 2017, she has led Lion TCR's efforts on product development and process optimisation in T cell immuno-therapy and the immuno-pathogenesis of hepatitis B virus infection.
Director of Research and Development Department
Dr Wai was an A*STAR scholar with over 15 years of experience in immunology research, in the fields of transplantation, cancer and HBV immunopathogenesis. She obtained her Ph.D. in Immunology from Stanford University, U.S.A. in 2010, focusing on immune cell interactions in liver transplantation and cancer. Since 2017, Dr Wai has led Lion TCR’s efforts to expand the TCR library and pipeline project.
Director of GMP Operation Department
Dr Wong has over 20 years of industry experiences in Manufacturing, Regulatory Affairs, Quality Assurance and Quality Control in pharmaceutical start-ups as well as a Regulatory Consultant with the Health Sciences Authority (HSA). He obtained PhD in Pharmacology from University of Sydney (1997).
Dr Josep M Llovet is the Founder and Director of the Liver Cancer Program and Full Professor of Medicine at the Mount Sinai School of Medicine, New York University (USA). He has been the President, Secretary and Founder of the International Liver Cancer Association (ILCA) and Chairman of the European Clinical Practice Guidelines of management of liver cancer (EASL-EORTC). He has also been recognised as the top 1% cited researcher in Thomson Reuters (2014-2016) and the most cited investigator in Spain (1997-2011). Dr Llovet has participated as principal investigator in many international randomized trials in HCC on novel targeted therapies. His breakthrough achievement establishes sorafenib as first-line standard of care treatment for advanced HCC, and represents the first indication of survival benefits with systemic treatments.
Dr Robert Thimme is the Medical Director of the Department of Medicine II at the University of Freiburg. He is a member of the American Society for Clinical Investigation, and Permanent Senate Commission on Key Questions in Clinical Research (SCCR). His research focus lies on the immune responses in hepatitis B virus (HBV), hepatitis C virus (HCV) infection and hepatocellular carcinoma (HCC). He has been in the editorial boards of journals such as Journal of Clinical Investigation, and Journal of Hepatology.
Dr Paul Eldridge is the Director at Advanced Cellular Therapeutics Facility, UNC Bone Marrow Transplant and Cellular Therapy Program. He is a cell production GMP expert who has successfully submitted multiple applications for cell therapy IND to FDA. His personal interests lie in chimeric antigen receptor T cells (CAR-Ts), hematopoietic stem cells and cancer immunotherapy. He is the chair of the FACT Standards Committee and a FACT Inspector of cellular therapy processing, as well as the co-chair of the WBMT Graft Processing Committee.
Dr Dario Campana is a professor at the Department of Paediatrics, Yong Loo Lin School of Medicine, National University of Singapore (NUS). His research focus lies in haematology, oncology and blood/marrow transplantation and he strives to develop novel and practical approaches to enhance the anti-cancer activity of immune cells. He is the inventor of 3rd generation CAR-T technology (4-1BB, CD16mAB) and discovered the early T-cell precursor leading to high cure rate of leukemia. He is the scientific founder of the biotechnology company UNUM Therapeutics.